12
Participants
Start Date
December 23, 2020
Primary Completion Date
October 24, 2022
Study Completion Date
October 24, 2022
Cabozantinib
PO (dose and schedule based upon dose level and nomogram)
Topotecan
IV, over 30 minutes (schedule based upon dose level)
Cyclophosphamide
IV, over 30 minutes (schedule based upon dose level)
Myeloid growth factor
subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
Boston Children's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
OTHER